ClinicalTrials.gg
RecruitingNCT07442006Updated Mar 2, 2026

Glycemic Variability of Combination Therapies in T2DM

A Phase 4 interventional study of Empagliflozin/Metformin and Anagliptin in Type 2 Diabetes Mellitus (T2DM), sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
37th of 130
178 · median 79
Started
2025
with 10 others
Phase 4
50 of 130
11 open now
Primary completion
2027-03
later than 9 of 18 live
Registered
123rd of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 37th largest by planned enrollment, is one of 11 that started in 2025, is one of 50 in phase 4, reaches primary completion later than 9 of the 18 other live ones, and was the 123rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Glycemic Variability of Combination Therapies in T2DM

Read the detailed description

A multicenter study to evaluate efficacy and safety

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Glycemic Variability
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.

Exclusion criteria

Exclusion Criteria:

  • History of acute or chronic metabolic acidosis
  • Moderate to severe renal impairment ( \< 45 mL/min/1.73m²)
  • Severe hepatic impairment
  • History of heart failure ( Class III/IV)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (estimated)

Study arms

  • Experimental
    Experimental

    Empagliflozin/Metformin + Anagliptin

    Drug: Empagliflozin/Metformin · Drug: Anagliptin

  • Active comparator
    Active Comparator

    Metformin + Empagliflozin/Linagliptin

    Drug: Metformin · Drug: Empagliflozin/Linagliptin

Interventions

  • DrugEmpagliflozin/Metformin

    Drug pages: Empagliflozin · Metformin

    5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)

  • 100 mg, for 12 weeks (PO, BID)

  • 500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)

  • DrugEmpagliflozin/Linagliptin

    Drug page: Empagliflozin/Linagliptin

    10/5 mg, for 12 weeks (PO, QD)

06

What researchers measure

Primary outcomes

  1. Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12

    Time frame: Baseline to week 12

Secondary outcomes

  1. Change in the percentage of time spent within the target glucose range (70-180 mg/dL)

    Time frame: Baseline to week 12

  2. Change from baseline in mean blood glucose at 12 weeks

    Time frame: Baseline to week 12

  3. Change from baseline in HbA1c at 12 weeks

    Time frame: Baseline to week 12

  4. Change from baseline in FPG at 12 weeks

    Time frame: Baseline to week 12

  5. Change from baseline in HOMA-β at 12 weeks

    HOMA- β: 20\*fasting insulin/\[(fasting plasma glucose\*0.0555)-3.5\]

    Time frame: Baseline to week 12

  6. Change from baseline in HOMA-IR at 12 weeks

    HOMA-IR: fasting insulin\*(fasting glucose\*0.0555)/22.5

    Time frame: Baseline to week 12

07

Study locations

1 of 1 sites recruiting
  • The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
    Seoul, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 17 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Mar 2, 2026
StartActual
Oct 29, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442006
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Oct 29, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Saemi Kang
Contact
kangsm@jwhealthcare.com
82-2-840-6902
Sung Rae Kim
principal investigator · The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin · Anagliptin

Start the discussion